- Trials with a EudraCT protocol (583)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
583 result(s) found for: Brain Cell.
Displaying page 1 of 30.
EudraCT Number: 2011-003618-18 | Sponsor Protocol Number: M10-897 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Su... | |||||||||||||
Medical condition: Brain metastases from NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) BE (Completed) CZ (Completed) FI (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005194-32 | Sponsor Protocol Number: CRANIAL | Start Date*: 2013-06-28 | ||||||||||||||||
Sponsor Name:Institut Jules Bordet | ||||||||||||||||||
Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer | ||||||||||||||||||
Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002109-58 | Sponsor Protocol Number: RSR13 RT-016 | Start Date*: 2005-02-14 | |||||||||||
Sponsor Name:ALLOS Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases... | |||||||||||||
Medical condition: Brain metastases from breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) GB (Completed) LT (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005247-10 | Sponsor Protocol Number: ITCC-003-Tarceva/Roche MO 18461 | Start Date*: 2005-07-29 |
Sponsor Name:The University Hospitals of Leicester NHS Trust | ||
Full Title: Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed... | ||
Medical condition: Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005647-24 | Sponsor Protocol Number: MIA2019/CT/258 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Melanoma Institute Australia | |||||||||||||
Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met... | |||||||||||||
Medical condition: melanoma brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000889-36 | Sponsor Protocol Number: H6Q-MC-S020 | Start Date*: 2006-08-10 |
Sponsor Name:Eli Lilly and Company limited | ||
Full Title: A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer | ||
Medical condition: brain metastastases of non-small or small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) SE (Completed) DK (Completed) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000578-20 | Sponsor Protocol Number: CLDK378A2205 | Start Date*: 2015-03-16 | |||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||||||||||||
Full Title: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to ... | |||||||||||||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001119-30 | Sponsor Protocol Number: 2B3-101-CR-001 | Start Date*: 2011-06-22 | |||||||||||||||||||||||||||||||
Sponsor Name:to-BBB technologies B.V. | |||||||||||||||||||||||||||||||||
Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma. | |||||||||||||||||||||||||||||||||
Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000425-27 | Sponsor Protocol Number: GECP21/02 | Start Date*: 2021-10-08 | |||||||||||
Sponsor Name:Fundación GECP | |||||||||||||
Full Title: Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases | |||||||||||||
Medical condition: Non-small cell lung cancer with brain metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005154-11 | Sponsor Protocol Number: GECP17/05 | Start Date*: 2018-05-31 | |||||||||||
Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP) | |||||||||||||
Full Title: Phase II non-randomized study of Atezolizumab (MPDL3280A) in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung c... | |||||||||||||
Medical condition: Atezolizumab combined with carboplatin and pemetrexed | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004451-38 | Sponsor Protocol Number: A6181092 | Start Date*: 2007-02-02 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer NSCLC patients with brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005545-37 | Sponsor Protocol Number: AIO-ZNS-0113(CaBaMet) | Start Date*: 2015-03-11 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) | |||||||||||||||||||||||
Medical condition: breast or lung cancer with recurrent or progressive brain metastases | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000678-41 | Sponsor Protocol Number: ET19-006 | Start Date*: 2019-05-13 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases | ||
Medical condition: Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019637-96 | Sponsor Protocol Number: YMB1000-018 | Start Date*: 2010-12-20 |
Sponsor Name:YMBiosciences INC | ||
Full Title: A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer | ||
Medical condition: Brain metastases from Non-Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004301-27 | Sponsor Protocol Number: NIBIT-M2 | Start Date*: 2012-11-08 | |||||||||||
Sponsor Name:FONDAZIONE NIBIT | |||||||||||||
Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis | |||||||||||||
Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003362-84 | Sponsor Protocol Number: FSJD-DIPG-DC | Start Date*: 2016-05-18 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG ) | |||||||||||||
Medical condition: Diffuse intrinsic pontine glioma (DIPG) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002074-22 | Sponsor Protocol Number: UM2005/00201/00 | Start Date*: 2006-10-18 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer. | ||
Medical condition: Brain metastases from primary non-small cell lung cancer (NSCLC). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002769-38 | Sponsor Protocol Number: 2603 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE | |||||||||||||
Full Title: A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES. | |||||||||||||
Medical condition: NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001017-37 | Sponsor Protocol Number: ICO-2020-28 | Start Date*: 2021-06-30 | |||||||||||||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||||||||||||
Full Title: PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer | |||||||||||||||||||||||
Medical condition: patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001749-13 | Sponsor Protocol Number: P04071 | Start Date*: 2005-02-22 |
Sponsor Name:AESCA Pharma GesmbH | ||
Full Title: Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy alone | ||
Medical condition: Patients with non small cell lung cancer (NSCLC) have a high risk of developing brain metastasis, up to 40% as evaluated in autopsy studies. These patients are often heavily symptomatic and their l... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.